Characteristics of the Patients at Baseline*

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年9月 25 日 8:20-8:50 B 棟8階 カンファレンス室.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Serum Selenium Levels and All-Cause, Cancer, and.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Glycated Hemoglobin Measurement and Prediction of.
The SPRINT Research Group
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
Copyright © 2009 American Medical Association. All rights reserved.
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
Career choice for Chinese medical graduate: Safety Physician
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.
TNT Study: Baseline Characteristics of the Patients
The Hypertension in the Very Elderly Trial (HYVET)
Fellström BC, et al. N Engl J Med 2009;360:1455-7
Diabetes Journal Club March 17, 2011
Plus–minus values are means ±SE
Daan Kromhout, et al. NEJM epub August 29, 2010
Enrollment and Outcomes
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Cumulative incidences of events, according to glucose-control strategy
Flow of Patients Through the Trial
Flow of Patients Through Trial
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Baseline Characteristics of the Study Participants
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.
Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.
RECORD Study: Enrollment and Outcomes
Volume 73, Issue 8, Pages (April 2008)
The ACCORD Study Group. NEJM 2010; Epub March 14
Baseline Characteristics of the Patients - Part I
Enrollment and Outcomes
The ACCORD Study Group. NEJM 2010; Epub March 14
Relative effects of glucose-control strategy on microvascular disease.
Primary outcome and patient reported secondary outcomes in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia receiving.
A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.
TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,
Presentation transcript:

Characteristics of the Patients at Baseline* * Plus–minus values are means ±SD. There were no significant differences between the two study groups at baseline. The bodymass index is the weight in kilograms divided by the square of the height in meters. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for potassium to millimoles per liter, multiply by 0.2558. To convert the values for creatinine to micromoles per liter, multiply by 88.4. † Race was selfreported, and patients could check multiple categories. ACCORD Study Group. NEJM 2008;358:2545-59

Median Glycated Hemoglobin Levels at Each Study Visit I bars denote interquartile ranges ACCORD Study Group. N Engl J Med 2008;358:2545-59

Prescribed Glucose-Lowering Drugs* ACCORD Study Group. N Engl J Med 2008;358:2545-59

Adverse Events, Clinical Measures, Tobacco Use, and Use of Nonglycemic Medication after Randomization* ACCORD Study Group. N Engl J Med 2008;358:2545-59

Primary and Secondary Outcomes* ACCORD Study Group. N Engl J Med 2008;358:2545-59

Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause ACCORD Study Group. N Engl J Med 2008;358:2545-59

Hazard Ratios for the Primary Outcome (A) and Death from Any Cause in Prespecified Subgroups Data regarding glycated hemoglobin levels at baseline are presented for 10,288 patients because a baseline level as not available for 23 patients. Horizontal bars represent the 95% confidence interval, and vertical dashed lines indicate the overall hazard ratio. The size of each square is proportional to the number of patients. ACCORD Study Group. NEJM 2008;358:2545-59